The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBatm Advanced Regulatory News (BVC)

Share Price Information for Batm Advanced (BVC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 19.65
Bid: 18.35
Ask: 19.95
Change: 0.00 (0.00%)
Spread: 1.60 (8.719%)
Open: 19.65
High: 0.00
Low: 0.00
Prev. Close: 19.65
BVC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

BATM enters option agreement to sell NGSoft

12 Jan 2021 07:00

RNS Number : 3160L
BATM Advanced Communications Ld
12 January 2021
 

LEI: 213800FLQUB9J289RU66

12 January 2021

 

BATM Advanced Communications Limited

("BATM" or "the Group")

 

BATM enters option agreement to sell NGSoft for c. $33m

Disposal of legacy software services subsidiary to generate funds for acceleration of core activities

 

BATM (LSE: BVC; TASE: BVC), a leading provider of real-time technologies for networking solutions and medical laboratory systems, announces that it has entered into an option agreement (the "Option Agreement") to sell NG Soft Ltd. ("NGSoft"), a subsidiary of the Group, for NIS 105.1m (approximately $33m) in cash to Aztek Technologies (1984) Ltd., a provider of ICT cloud services in Israel and a portfolio company of SKY Fund (the "Buyer").

 

Background to the transaction

 

BATM is focused on core areas of activity, underpinned by the Group's portfolio of intellectual property, that it expects will offer transformational growth opportunities in both its Networking & Cyber and Bio-Medical divisions. In particular, in 2020, the Group achieved fundamental milestones in progressing the development of its network function virtualisation ("NFV") activities, including a successful proof-of-concept of its NFVTime solution with Vodafone and securing its first tier 1 customer with a multi-year licensing agreement. In medical diagnostics, the Bio-Medical division rapidly produced multiple solutions in response to the COVID-19 outbreak that are experiencing substantial demand as the global pandemic continues.

 

As previously stated, BATM continuously seeks opportunities to unlock shareholder value from Group subsidiaries that are considered non-core to the future of the Group. NGSoft is a software and digital services company that provides creative digital and technology solutions. Its development activities do not include any of the Group's NFV or cyber solutions. Accordingly, the Board believes that it would be in the best interests of BATM and of all shareholders to generate value from the sale of NGSoft and invest the proceeds to accelerate the Group's core activities in accordance with its strategic plan.

 

Terms of the transaction

 

Under the terms of the Option Agreement, BATM has the option, but not obligation, to sell the entire issued share capital of NGSoft for a total cash consideration of NIS 105.1m (c. $33m), of which the Group would receive a total of NIS 93.7m (c. $29m). The Group's consideration includes a NIS 15.5m loan repayment from NGSoft and a NIS 2.1m dividend payment, both to be received upon the exercise of the option. Certain employees of NGSoft would receive the balance of NIS 11.4m through cash out of their employee options and rights on completion.

 

In the event that the option is exercised by BATM, a share purchase agreement would be entered into - the final form of which has been agreed with the signatory pages being held in escrow by a trustee who would be required to release them upon being served with a notice of exercise of the option. The Buyer only has the right to terminate the agreement in the event of a material adverse change in the trading of NGSoft.

 

The Group's option is exercisable up to and including 1 March 2021, which, in accordance with the terms of the Option Agreement, can be extended by the Group to 17 May 2021 under certain predefined circumstances. If the Group does not exercise its option, it will be required to pay the Buyer a consideration of up to NIS 7.9m in cash.

 

The Group will update the market in due course.

 

 

Enquiries:

 

BATM Advanced Communications

Dr Zvi Marom, Chief Executive Officer

+972 9866 2525

Moti Nagar, Chief Financial Officer

Shore Capital

Mark Percy, Anita Ghanekar, James Thomas (Corporate Advisory)

Henry Willcocks (Corporate Broking)

+44 20 7408 4050 

Luther Pendragon

Harry Chathli, Claire Norbury

+44 20 7618 9100

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
AGRDKDBBCBKDBDD
Date   Source Headline
14th Apr 20229:30 amRNSAnnual Financial Report
13th Apr 20227:00 amRNSAppointment of Non-Executive Director
4th Apr 20227:00 amRNSTransaction in Own Shares and TVR
18th Mar 20227:00 amRNSStrategic Partnership for Edgility with NEXCOM
17th Mar 202210:30 amRNSResult of General Meeting
10th Mar 202212:30 pmRNSHolding(s) in Company
8th Mar 202211:30 amRNSHolding(s) in Company
28th Feb 20227:00 amRNSFull Year Results
23rd Feb 20227:00 amRNSNotice of General Meeting
21st Feb 20227:00 amRNSStrategic Partnership for Edgility with Advantech
17th Feb 20227:00 amRNSTrading Update and Notice of Results
3rd Feb 202211:23 amRNSClarification on FTSE Nationality Review
3rd Feb 20227:00 amRNSUpdate on FTSE Nationality Review & Share Buyback
31st Jan 20227:00 amRNSUpdate on Ador Diagnostics
17th Jan 20227:00 amRNSUpdate on FTSE Nationality Review
4th Jan 20227:00 amRNSDividend Declaration
4th Jan 20227:00 amRNSTotal Voting Rights
16th Dec 20217:00 amRNSFirst sales of rapid COVID-19 test in Russia
14th Dec 202111:45 amRNSResult of AGM and Dividend Declaration
30th Nov 20217:00 amRNSCOVID-19 tests effective in diagnosing Omicron
25th Nov 20213:00 pmRNSBlock Listing Interim Review
22nd Nov 20213:00 pmRNSNotice of AGM and Dividend Declaration
10th Nov 20217:00 amRNSBATM receives $3.5m cyber security contract
3rd Nov 20217:00 amRNSNew five-year contract for Edgility
1st Nov 20217:00 amRNSBATM receives agri-waste contract in Botswana
7th Oct 20217:00 amRNSStrategic partnership for NFV with AudioCodes
13th Sep 20217:00 amRNSFirst enterprise customer for NFV with $2m order
23rd Aug 20217:00 amRNSInterim Results
12th Aug 20217:00 amRNSNotice of Results
12th Jul 20217:00 amRNSLaunch of Edgility networking NFV-based ecosystem
5th Jul 20217:00 amRNSBATM receives $10m cyber security contract
15th Jun 20217:00 amRNSBATM receives $4.1m cyber security contract
26th May 20217:00 amRNSBlock listing Interim Review
18th May 20217:00 amRNSBATM commences delivery of new COVID-19 tests
19th Apr 202110:25 amRNSAnnual Financial Report
12th Apr 20217:00 amRNSStrategic partnership for NFV
29th Mar 20217:00 amRNSBATM develops molecular diagnostics test for TB
19th Mar 20217:00 amRNSCompletion of Sale of NGSoft
11th Mar 20217:00 amRNSBATM launches no-swab saliva-based COVID-19 test
1st Mar 20217:00 amRNSUpdate on Sale of NGSoft
22nd Feb 20217:00 amRNSFull Year Results
11th Feb 20215:38 pmRNSFTSE Nationality Review
1st Feb 20217:00 amRNSTrading Update and Notice of Results
19th Jan 20217:00 amRNSBATM's NFVTime now available for the public cloud
12th Jan 20217:00 amRNSBATM enters option agreement to sell NGSoft
24th Dec 20207:00 amRNSCOVID-19 test effective in diagnosing new strain
17th Dec 20203:50 pmRNSResult of AGM
15th Dec 20207:00 amRNSUpdate on Ador Diagnostics
7th Dec 20207:00 amRNSDelivery of First Insect Protein Recovery Facility
30th Nov 20203:03 pmRNSTotal Voting Rights and Share Capital

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.